PERCEPTIVE INFORMATICS INTRODUCES DATALABS® 5.0 EDC SOLUTION, UNLOCKING NEW CLINICAL TRIAL PROCESS EFFICIENCIES
Boston, MA, March 29, 2011 — Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today unveiled the new release of its DataLabs® Electronic Data Capture (EDC) solution, which provides richer functionality to further streamline the clinical trial process. The DataLabs 5.0 EDC solution enables clinical trial sponsors to more efficiently manage the clinical development process from study design to collection and reporting of study data. Unlike other EDC solutions, the DataLabs EDC solution benefits from seamless interoperability with other systems in the Perceptive eClinical Suite to provide real-time data interchange and enable more effective decision making for clinical development programs.
“For nearly 15 years we have been helping the biopharmaceutical industry use EDC-driven solutions in development programs to capture clinical trial data. We view EDC as a key component in a complete eClinical solution,” said Nicholas Richards, Vice President, Product Development, Perceptive Informatics. “The latest release of the DataLabs 5.0 EDC solution provides advanced features, powered by our eClinical platform, which will set a new direction for how we look at study design and deployment across traditionally isolated systems.”
Perceptive offers the DataLabs EDC solution, as well as other solutions in its eClinical Suite, as a software-as-a-service (SaaS) application, which is entirely hosted, maintained and supported by Perceptive’s quality-assured eClinical platform. Newly enhanced features of the DataLabs 5.0 EDC solution, which has a user-friendly interface, include a powerful reporting engine, web-based study design tool, and sophisticated search function, as well as advanced export functionality to easily extract EDC data.
Perceptive has incorporated a unique level of convergence into its eClinical Suite, which allows the functionality that exists in one application to be accessed through another. The convergence between the Perceptive DataLabs EDC solution and Randomization and Trial Supply Management (RTSM) technologies allow users to randomize and dispense medication from either system. With new dynamic forms and visit functionality available in the DataLabs 5.0 EDC solution, any changes that are made within the RTSM technologies will automatically trigger within the EDC system a dynamic patient visit to occur. This capability effectively supports mid-study protocol amendments commonly required in adaptive trials.
Perceptive experts will provide demonstrations of the newly released DataLabs 5.0 EDC solution at Booth #807 in the exhibit hall during the 20th Annual Partnerships in Clinical Trials conference, being held March 30 - April 1 in Phoenix, Arizona.
# # #
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive eClinical Suite visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.